Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Paul Tudor Jones` Stock Picks

|Includes: FANH, Progenics Pharmaceuticals Inc. (PGNX)

According to, Paul Tudor Jones top holdings are two almost unknown stocks, a chinese insurance company CNinsure Inc. (NASDAQ:CISG) and a small cap biotech, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

That is very interesting and I would bet alongside Paul anytime. He has been one of the best money manager in Wall Street for decades.

They are both well below their 52 week highs, so there is no risk of buying overextended stocks:

Here`s a short summary of both companies:

CNinsure Inc. is an independent insurance intermediary company operating in China. The Company had 48,693 sales professionals, 1,421 claims adjustors and 571 sales and service outlets operating in 23 provinces as of April 15, 2010. As an insurance intermediary company, it does not assume underwriting risks. The Company distributes to customers in China a range of property, casualty and life insurance products underwritten by domestic and foreign insurance companies operating in China and provides insurance claims adjusting services, such as damage assessment, survey, authentication and loss estimation. It also provides services, such as around-the-clock emergency services and assistance with claim settlement, to its customers, individuals and institutions that purchase insurance products through CNinsure. In July 2010, CNinsure announced the acquisition of InsCom Holding Limited.

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The Company’s principal programs are directed towards supportive care, oncology and virology. In supportive care, the Company’s first commercial product is RELISTOR (methylnaltrexone bromide) subcutaneous injection, a therapy for opioid-induced constipation (NYSE:OIC) approved for sale in over 40 countries worldwide. In the area of prostate cancer, Progenics is conducting a Phase I clinical trial of a fully human monoclonal antibody-drug conjugate (NYSE:ADC) directed against prostate specific membrane antigen (PSMA). In the area of virology, the Company is developing a viral-entry inhibitor (a humanized monoclonal antibody), PRO 140, for infection due to human immunodeficiency virus (HIV) that causes acquired immunodeficiency syndrome (AIDS).

Disclosure: No positions